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Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient reported outcome measure that 
enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results 
of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Arabic language. The 
reading comprehension of the questionnaire was tested in 10 JIA parents and patients. Each participating centre was asked 
to collect demographic and clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive patients seen in 
a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical validation phase 
explored descriptive statistics and the psychometric issues of the JAMAR: the 3 Likert assumptions, floor/ceiling effects, 
internal consistency, Cronbach’s alpha, interscale correlations, test–retest reliability, and construct validity (convergent 
and discriminant validity). A total of 100 JIA patients (27.0% systemic JIA, 23.0% oligoarticular, 25.0% RF negative pol-
yarthritis, and 25.0% other categories) and 100 healthy children, were enrolled in one paediatric rheumatology centre. The 
JAMAR components discriminated well healthy subjects from JIA patients. All JAMAR components revealed satisfactory 
psychometric performances. In conclusion, the Arabic version of the JAMAR is a valid tool for the assessment of children 
with JIA and is suitable for use both in routine clinical practice and in clinical research.
Keywords Juvenile idiopathic arthritis · Disease status · Functional ability · Health-related quality of life · JAMAR
Introduction
The aim of the present study was to cross-culturally adapt 
and validate the Arabic parent, child/adult version of the 
Juvenile Arthritis Multidimensional Assessment Report 
(JAMAR) [1] in patients with juvenile idiopathic arthritis 
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(JIA). The JAMAR assesses the most relevant parent/patient 
reported outcomes in JIA, including overall well-being, 
functional status, health-related quality of life (HRQoL), 
pain, morning stiffness, disease activity/status/course, 
articular and extra-articular involvement, drug-related side 
effects/compliance, and satisfaction with illness outcome.
This project was part of a larger multinational study con-
ducted by the Paediatric Rheumatology International Trials 
Organization (PRINTO) [2] aimed to evaluate the Epide-
miology, Outcome and Treatment of Childhood Arthritis 
(EPOCA) in different geographic areas [3].
We report herein the results of the cross-cultural adapta-
tion and validation of the parent and patient versions of the 
JAMAR in the Arabic language.
Materials and methods
The methodology employed has been described in detail in 
the introductory paper of the supplement [4]. In brief, it was 
a cross-sectional study of JIA children, classified according 
to the ILAR criteria [5, 6] and enrolled from January 2012 
to January 2016. Children were recruited after Ethics Com-
mittee approval and consent from at least one parent.
The JAMAR
The JAMAR [1] includes the following 15 sections:
 1. Assessment of physical function (PF) using 15-items 
in which the ability of the child to perform each task 
is scored as follows: 0 = without difficulty, 1 = with 
some difficulty, 2 = with much difficulty, 3 = unable to 
do and not applicable if it was not possible to answer 
the question or the patient was unable to perform the 
task due to their young age or to reasons other than 
JIA. The total PF score ranges from 0 to 45, and has 
three components: PF-lower limbs (PF-LL); PF-hand 
and wrist (PF-HW) and PF-upper segment (PF-US) 
each scoring from 0 to 15 [7]. Higher scores indicate 
higher degree of disability [8–10].
 2. Rating of the intensity of the patient’s pain on a 
21-numbered circle visual analogue scale (VAS) [11].
 3. Assessment of the presence of joint pain or swelling 
(present/absent for each joint).
 4. Assessment of morning stiffness (present/absent).
 5. Assessment of extra-articular symptoms (fever and 
rash) (present/absent).
 6. Rating of the level of disease activity on a 21-circle 
VAS.
 7. Rating of disease status at the time of the visit (cat-
egorical scale).
 8. Rating of disease course from previous visit (categori-
cal scale).
 9. Checklist of the medications the patient is taking (list 
of choices).
 10. Checklist of side effects of medications.
 11. Report of difficulties with medication administration 
(list of items).
 12. Report of school/university/work problems caused by 
the disease (list of items).
 13. Assessment of HRQoL, through the Physical Health 
(PhH), and Psychosocial Health (PsH) subscales (5 
items each) and a total score. The four-point Likert 
response, referring to the prior month, are ‘never’ 
(score = 0), ‘sometimes’ (score = 1), ‘most of the time’ 
(score = 2) and ‘all the time’ (score = 3). A ‘not assess-
able’ column was included in the parent version of the 
questionnaire to designate questions that cannot be 
answered because of developmental immaturity. The 
total HRQoL score ranges from 0 to 30, with higher 
scores indicating worse HRQoL. A separate score for 
PhH and PsH (range 0–15) can be calculated. [12–14].
 14. Rating of the patient’s overall well-being on a 21-num-
bered circle VAS.
 15. A question about satisfaction with the outcome of 
the illness (yes/no) [15].The JAMAR is available in 
three versions, one for parent proxy-report (child’s age 
2–18), one for child self-report, with the suggested age 
range of 7–18 years, and one for adults.
Cross‑cultural adaptation and validation
The process of cross-cultural adaptation was conducted 
according to international guidelines with 2–3 forward and 
backward translations. In those countries for which the trans-
lation of JAMAR had been already cross-cultural adapted in 
a similar language (i.e., Spanish in South American coun-
tries), only the probe technique was performed.. Reading 
comprehension and understanding of the translated ques-
tionnaires were tested in a probe sample of ten JIA parents 
and ten patients.
Each participating centre was asked to collect demo-
graphic, clinical data, and the JAMAR in 100 consecutive 
JIA patients or all consecutive patients seen in a 6-month 
period and to administer the JAMAR to 100 healthy children 
and their parents.
The statistical validation phase explored the descriptive 
statistics and the psychometric issues [16]. In particular, we 
evaluated the following validity components: the first Likert 
assumption (mean and standard deviation [SD] equivalence); 
the second Likert assumption or equal item-scale correla-
tions (Pearson r: all items within a scale should contribute 
equally to the total score); the third Likert assumption (item 
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internal consistency or linearity for which each item of a 
scale should be linearly related to the total score, that is, 
90% of the items should have Pearson r ≥ 0.4); floor/ceiling 
effects (frequency of items at lower and higher extremes of 
the scales, respectively); internal consistency, measured by 
the Cronbach’s alpha, interscale correlation (the correlation 
between two scales should be lower than their reliability 
coefficients, as measured by Cronbach’s alpha); test–retest 
reliability or intraclass correlation coefficient (reproducibil-
ity of the JAMAR repeated after 1 or 2 weeks); and construct 
validity in its two components: the convergent or external 
validity which examines the correlation of the JAMAR sub-
scales with the six JIA core-set variables, with the addition 
of the parent assessment of disease activity and pain by the 
Spearman’s correlation coefficients (r) [17] and the discri-
minant validity, which assesses whether the JAMAR dis-
criminates between the different JIA categories and healthy 
children [18].
Quantitative data were reported as medians with first and 
third quartiles and categorical data as absolute frequencies 
and percentages.
The complete Arabic parent and patient versions of the 
JAMAR are available upon request to PRINTO.
Results
Cross‑cultural adaptation
The Arabic JAMAR was fully cross-culturally adapted from 
the standard English version with three forward and two 
backward translations.
The concordance rate between the original standard Eng-
lish version of the JAMAR and the two back-translations 
was 90.2% (111/123 lines) for the parent version and 72.5% 
(87/120 lines) for the child version.
All 123 lines of the parent version of the JAMAR 
were understood by at least 80% of the 10 parents tested 
(median = 100%; range 90–100%). Of the 120 lines in 
the patient version of the JAMAR, 118 (98%) lines were 
understood by at least 80% of the children (median = 100%; 
range 60–100%). Lines 17 and 71 of the child version of the 
JAMAR were modified considering patients’ suggestions.
Demographic and clinical characteristics 
of the subjects
A total of 100 JIA patients and 100 healthy children (total 
of 200 subjects) were enrolled at the King Faisal Specialist 
Hospital and Research Center, Riyadh.
In the 100 JIA subjects, the JIA categories were 27.0% 
with systemic JIA, 23.0% with oligoarthritis, 25.0% with RF 
negative polyarthritis, 13.0% with RF positive polyarthritis, 
6.0% with psoriatic arthritis, 3.0% with enthesitis-related 
arthritis, and 3.0% with undifferentiated arthritis (Table 1).
A total of 199/200 (99.5%) subjects had the parent ver-
sion of the JAMAR completed by a parent (99 from parents 
of JIA patients and 100 from parents of healthy children). 
The JAMAR was completed by 143/199 (71.9%) mothers 
and 56/199 (28.1%) fathers. The child version of the JAMAR 
was completed by 187/200 (93.5%) children age 5.0 or older. 
In addition, patients younger than 7 years old, capable to 
assess their personal condition and able to read and write, 
were asked to fill in the patient version of the questionnaire.
Discriminant validity
The JAMAR results are presented in Table 1, including the 
scores [median (first–third quartile)] obtained for the PF, 
the PhH, the PsH subscales, and total score of the HRQoL 
scales. The JAMAR components discriminated well between 
healthy subjects and JIA patients.
In summary, the JAMAR revealed that JIA patients had 
a greater level of disability and pain, as well as a lower 
HRQoL than their healthy peers.
Psychometric issues
The main psychometric properties of both parent and child 
versions of the JAMAR are reported in Table 2. The follow-
ing “Results” section refers mainly to the parent’s version 
findings, unless otherwise specified.
Descriptive statistics (first Likert assumption)
There were no missing results for all JAMAR items, since 
data were collected through a web-based system that 
did not allow skipping answers and input of null values. 
The response pattern for both PF and HRQoL was posi-
tively skewed toward normal functional ability and normal 
HRQoL. All response choices were used for the different 
HRQoL items except for items 9 and 10, whereas a reduced 
number of response choices was used for all the PF items 
except for items 3 and 4. The mean and SD of the items 
within a scale were roughly equivalent for the PF and for 
the HRQoL items (data not shown). The median number of 
items marked as not applicable was 0% (0–0%) for the PF 
and 0% (0–2%) for the HRQoL.
Floor and ceiling effect
The median floor effect was 87.9% (75.8–91.9%) for the 
PF items, 65.7% (61.6–76.8%) for the HRQoL PhH items, 
and 77.8% (69.7–84.8%) for the HRQoL PsH items. The 
median ceiling effect was 0% (0–0.0%) for the PF items, 
2.0% (2.0–4.0%) for the HRQoL PhH items, and 1.0% 
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Table 1  Descriptive statistics (medians, first–third quartiles or absolute frequencies and %) for the 100 JIA patients
Data related to the JAMAR refer to the 99 JIA patients and to the 100 healthy subjects for whom the questionnaire has been completed by the 
parents
JAMAR Juvenile Arthritis Multidimensional Assessment Report; ESR erythrocyte sedimentation rate; MD medical Doctor; VAS visual analogue 
scale (score 0–10; 0 = no activity, 10 = maximum activity); LOM limitation of motion; ANA anti-nuclear antibodies; PF physical function (total 
score ranges from 0 to 45); HRQoL health-related quality of life (total score ranges from 0 to 30); PhH physical health (total score ranges from 0 
to 15); PsH psychosocial health (total score ranges from 0 to 15)
p values refer to the comparison of the different JIA categories or to JIA versus healthy. *p < 0.05, **p < 0.001, #p < 0.0001
Systemic Oligoarthritis RF − polyar-
thritis
RF + polyar-
thritis
Psoriatic 
arthritis
Enthesitis-
related 
arthritis
Undifferenti-
ated arthritis
All JIA 
patients
Healthy
N = 27 N = 23 N = 25 N = 13 N = 6 N = 3 N = 3 N = 100 N = 100
Female 11 (40.7%) 15 (65.2%) 19 (76%) 12 (92.3%) 2 (33.3%) 1 (33.3%) 3 (100%) 63 (63%) 47 (47%)*
Age at visit 10.1 (8–13.2) 9.2 (6.7–9.9) 11 (10.2–
12.3)
11.4 
(9.9–12.9)
10.9 
(9.4–11.8)
12.6 (12.3–
12.6)
9.2 (1.9–13.3) 10.2 (8.6–
12.3)*
9.4 (7.3–
10.8)*
Age at onset 3.6 (1.7–7.1) 3.6 (2.3–5.2) 5.6 (2–8) 4.1 (3.1–8.2) 6.3 (4–10) 10.7 
(9.5–11.3)
6.9 (1.9–8.5) 4.5 (2.3–7.5)*
Disease duration 5.6 (3.1–7.4) 4.8 (2.5–6.7) 4.7 (3.3–7.7) 5.7 (3.6–8.4) 3.2 (1.3–6.4) 1.9 (1.3–2.8) 2.4 (0.1–4.8) 5 (2.6–7.3)
ESR 13 (6–28) 10.5 (7–27) 12 (6.5–31) 9.5 (6–23) 13 (6–27) 11 (7–15) 33 (7–59) 12 (7–27)
MD VAS 
(0–10 cm)
1 (0–5.5) 1 (0–2.5) 1 (0–3.5) 2.5 (0–4) 0.8 (0–2) 4 (1.5–4.5) 2 (0–3) 1 (0–4)
No. swollen joints 0 (0–1) 0 (0–1) 0 (0–2) 1 (0–2) 0.5 (0–1) 0 (0–2) 0 (0–0) 0 (0–1)
No. joints with 
pain
0 (0–4) 0 (0–1) 0 (0–3) 3 (0–6) 0.5 (0–1) 2 (2–8) 2 (0–2) 0 (0–2.5)
No. joints with 
LOM
0 (0–6) 0 (0–1) 0 (0–2) 0 (0–3) 0 (0–1) 1 (0–2) 1 (0–2) 0 (0–2)
No. active joints 0 (0–6) 0 (0–1) 0 (0–2) 2 (0–3) 0.5 (0–1) 0 (0–2) 0 (0–1) 0 (0–2)
Active systemic 
features
1 (3.7%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (1%)
ANA status 1 (3.7%) 7 (30.4%) 3 (12%) 4 (30.8%) 0 (0%) 0 (0%) 0 (0%) 15 (15%)
Uveitis 1 (3.7%) 5 (21.7%) 0 (0%) 2 (15.4%) 0 (0%) 0 (0%) 0 (0%) 8/99 (8.1%)
PF total score 2.5 (0–6) 0 (0–1) 2 (1–3) 1 (0–5) 0 (0–7) 1 (0–1) 9 (1–9) 1 (0–5) 0 (0–0)#
Pain VAS 3 (0–4.5) 0 (0–3) 2 (0–3.5) 1.5 (0–2.5) 0.3 (0–5.5) 1 (0–4) 1.5 (0–10) 1 (0–4) 0 (0–0)#
Disease activity 
VAS
1 (0–5) 0.5 (0–2) 1.5 (0–4) 1.5 (0–2) 0 (0–4) 1.5 (0–5) 0.5 (0–3) 0.5 (0–4)
Well–being VAS 0.3 (0–5) 0 (0–1.5) 2 (0–4) 1 (0–2) 0.3 (0–1) 1 (0.5–4.5) 1.5 (0–5) 0.5 (0–3.5)
HRQoL PhH 1.5 (0–4) 0 (0–1) 1 (1–3) 1 (0–5) 0 (0–5) 1 (0–4) 6 (0–7) 1 (0–4) 0 (0–0)#
HRQoL PsH 1.5 (0–4) 0 (0–1) 1 (0–2) 0 (0–0) 0 (0–3) 0 (0–1) 2 (0–4) 0 (0–2) 0 (0–0)#
HRQoL Total 
Score
3.5 (0–9) 0 (0–2) 3 (1–6) 1 (0–6) 1.5 (0–5) 1 (0–5) 6 (2–17) 1 (0–6) 0 (0–0)#
Pain/swell. in > 1 
joint
11/26 (42.3%) 9 (39.1%) 14 (56%) 9 (69.2%) 3 (50%) 2 (66.7%) 1 (33.3%) 49/99 (49.5%) 0 (0%)#
Morning stiff-
ness > 15 min
4/26 (15.4%) 3 (13%) 2 (8%) 3 (23.1%) 2 (33.3%) 1 (33.3%) 0 (0%) 15/99 (15.2%) 0 (0%)#
Subjective remis-
sion
11/26 (42.3%) 8 (34.8%) 13 (52%) 7 (53.8%) 2 (33.3%) 2 (66.7%) 0 (0%) 43/99 (43.4%)
In treatment 19/26 (73.1%) 13 (56.5%) 19 (76%) 11 (84.6%) 5 (83.3%) 3 (100%) 3 (100%) 73/99 (73.7%)
Reporting side 
effects
7/19 (36.8%) 2/13 (15.4%) 7/19 (36.8%) 4/11 (36.4%) 1/5 (20%) 1 (33.3%) 1 (33.3%) 23/73 (31.5%)
Taking medication 
regularly
15/19 (78.9%) 11/13 (84.6%) 16/19 (84.2%) 10/11 (90.9%) 4/5 (80%) 3 (100%) 2 (66.7%) 61/73 (83.6%)
With problems 
attending school
2/9 (22.2%) 0 (0%) 1/17 (5.9%) 1/8 (12.5%) 1/5 (20%) 1 (33.3%) 0 (0%) 6/60 (10%) 0 (0%)*
Satisfied with dis-
ease outcome
13/26 (50%) 17 (73.9%) 13 (52%) 11 (84.6%) 4 (66.7%) 3 (100%) 2 (66.7%) 63/99 (63.6%)
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(0–1.0%) for the HRQoL PsH items. The median floor 
effect was 41.4% for the pain VAS, 44.4% for the disease 
activity VAS, and 44.4% for the well-being VAS. The 
median ceiling effect was 3.0% for the pain VAS, 1.0% 
for the disease activity VAS, and 1.0% for the well-being 
VAS.
Equal item‑scale correlations (second Likert 
assumption)
Pearson item-scale correlations corrected for overlap were 
roughly equivalent for items within a scale for 93% of the 
Table 2  Main psychometric characteristics between the parent and child version of the JAMAR
JAMAR Juvenile Arthritis Multidimensional Assessment Report; JIA juvenile idiopathic arthritis; VAS visual analogue scale; PF physical func-
tion; HRQoL health-related quality of life; PhH physical Health; PsH psychosocial health; PF-LL PF-lower limbs; PF-HW PF-hand and wrist; 
PF-US PF-upper segment
Parent N = 99/199 Child N = 92/187
Missing values (first–third quartiles) No missing values No missing values
Response pattern PF and HRQoL positively skewed PF and HRQoL positively skewed
Floor effect, median
 PF (%) 87.9 88.0
 HRQoL PhH (%) 65.7 67.4
 HRQoL PsH (%) 77.8 83.7
 Pain VAS (%) 41.4 38.0
 Disease activity VAS (%) 44.4 41.3
 Well-being VAS (%) 44.4 44.6
Ceiling effect, median
PF (%) 0.0 0.0
 HRQoL PhH (%) 2.0% 3.3
 HRQoL PsH (%) 1.0 1.1
 Pain VAS (%) 3.0 4.3
 Disease activity VAS (%) 1.0 3.3
 Well-being VAS (%) 1.0 1.1
Items with equivalent item-scale correlation 93% for PF, 90% for HRQoL 93% for PF, 70% for HRQoL
Items with item-scale correlation ≥ 0.4 93% for PF, 100% for HRQoL 67% for PF, 70% for HRQoL
Cronbach’s alpha
 PF-LL 0.82 0.85
 PF-HW 0.82 0.54
 PF-US 0.71 0.68
 HRQoL PhH 0.84 0.84
 HRQoL PsH 0.84 0.64
Items with item-scale correlation lower than the Cronbach alpha 100% for PF, 100% for HRQoL 93% for PF, 100% for HRQoL
Test–retest intraclass correlation
 PF total score 1.0 0.99
 HRQoL PhH 1.0 1.0
 HRQoL PsH 1.0 1.0
Spearman correlation with JIA core-set variables, median
 PF 0.6 0.5
 HRQoL PhH 0.6 0.6
 HRQoL PsH 0.4 0.3
 Pain VAS 0.5 0.5
 Disease activity VAS 0.6 0.5
 Well-being VAS 0.6 0.6
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PF items, with the exception of PF item 15, and for 90% of 
the HRQoL items, with the exception of HRQoL item 1.
Item internal consistency (third Likert assumption)
Pearson item-scale correlations were ≥ 0.4 for 93% of items 
of the PF (except for PF item 15) and 100% of items of the 
HRQoL.
Cronbach’s alpha internal consistency
Cronbach’s alpha was 0.82 for PF-LL, 0.82 for PF-HW, and 
0.71 for PF-US. Cronbach’s alpha was 0.84 for HRQoL PhH 
and 0.84 for HRQoL PsH.
Interscale correlation
The Pearson correlation of each item of the PF and the HRQoL 
with all items included in the remaining scales of the question-
naires was lower than the Cronbach’s alpha.
Test–retest reliability
Reliability was assessed in 10 JIA patients, by re-administering 
both versions (parent and child) of the JAMAR after a median 
of 0 day (0–0 days). The intraclass correlation coefficients 
(ICC) for the PF total score showed an almost perfect repro-
ducibility (ICC = 1.0). The ICC for the HRQoL PhH and for 
the HRQoL PsH scores showed an almost perfect reproduc-
ibility (ICC = 1.0, for both).
Convergent validity
The Spearman correlation of the PF total score with the 
JIA core set of outcome variables ranged from 0.4 to 0.6 
(median = 0.6). The PF total score best correlation was 
observed with the parent assessment of pain (r = 0.7, 
p < 0.001). For the HRQoL, the median correlation of the PhH 
with the JIA core set of outcome variables ranged from 0.5 to 
0.7 (median = 0.6), whereas that for the PsH ranged from 0.3 to 
0.6 (median = 0.4). The PhH showed the best correlation with 
the parent’s assessment of pain (r = 0.8, p < 0.001) and the PsH 
with the physician global assessment of well-being (r = 0.6, 
p < 0.001). The median correlations between the pain VAS, the 
well-being VAS, and the disease activity VAS and the physi-
cian-centred, and laboratory measures were 0.5 (0.5–0.6), 0.6 
(0.5–0.7), and 0.6 (0.5–0.7), respectively.
Discussion
In this study, the Arabic version of the JAMAR was fully 
cross-culturally adapted from the original Standard Eng-
lish version with three forward and two backward transla-
tions. According to the results of the validation analysis, 
the Arabic parent and patient versions of the JAMAR pos-
sess satisfactory psychometric properties. The disease-spe-
cific components of the questionnaire discriminated well 
between patients with JIA and healthy controls.
Psychometric performances were good for all domains 
of the JAMAR with few exceptions: 1 PF item (“bite a 
sandwich or an apple”) showed a lower item’s internal 
consistency. However, the overall internal consistency was 
good for all the domains.
In the external validity evaluation, the Spearman’s cor-
relations of the PF and HRQoL scores with JIA core-set 
parameters ranged from moderate to strong.
The results obtained for the parent version of the 
JAMAR are very similar to those obtained for the child 
version, which suggests that children are equally reliable 
proxy reporters of their disease and health status as their 
parents. The JAMAR is aimed to evaluate the side effects 
of medications and school attendance, which are other 
dimensions of daily life than most of the previously used 
HRQoL tools. This may provide useful information for 
intervention and follow-up in health care.
In conclusion, the Arabic version of the JAMAR was 
found to have satisfactory psychometric properties, and it 
is, thus, a reliable and valid tool for the multidimensional 
assessment of children with JIA.
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